Understanding the progression of advanced medullary thyroid cancer
Official title: Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management
Run by M.D. Anderson Cancer Center · NCT04216732 · Data updated 2026-11-12
This study is trying to learn more about how advanced medullary thyroid cancer develops and affects patients' lives by collecting health information and feedback from those living with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2030 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 2 sites (San Francisco, California and 1 other locations) |
| Status | Recruiting |
| Started | January 10, 2020 |
| Main results expected | September 1, 2028 |
| Study ends | September 1, 2028 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT04216732 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with medullary thyroid cancer at any disease phase who are registrants in the Medullary Thyroid Cancer Registry.
✕Probably not a fit
Patients with early-stage medullary thyroid cancer or those not registered in the Medullary Thyroid Cancer Registry may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study utilizes a multi-institutional registry to explore the natural history of advanced medullary thyroid cancer (MTC). It aims to collect and analyze demographic, clinical, pathologic, and genotypic data to understand how MTC develops and progresses. Patients will complete questionnaires about their health, quality of life, and the impact of the disease on their lives multiple times a year. The study also seeks to identify predictors of disease progression and evaluate patient-reported outcomes related to treatment adherence and quality of life.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with advanced medullary thyroid cancer.
How similar studies have gone: Other studies focusing on the natural history of cancer have shown success in improving understanding and management of the disease, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR
Where it's running
-
University of California San Francisco
San Francisco, California, United States Recruiting -
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Elizabeth G Grubbs — M.D. Anderson Cancer Center
- Study coordinator: Elizabeth G Grubbs
- Email: eggrubbs@mdanderson.org
- Phone: 713-792-6940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Decision aid for patients with medullary thyroid cancer and their caregivers
This study is testing a new tool to help patients with medullary thyroid cancer and their caregivers make better choices about treatment and care options.
-
XL092 (zanzalintinib) for locally advanced or metastatic radioiodine‑refractory differentiated thyroid cancer
This trial tests whether XL092 (zanzalintinib), an oral tyrosine kinase inhibitor, can keep radioiodine‑refractory differentiated thyroid cancer from getting worse in adults with locally advanced or metastatic disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.